Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
167 hedge funds and large institutions have $1.41B invested in Array Biopharma Inc in 2016 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 62 increasing their positions, 42 reducing their positions, and 35 closing their positions.
72% more call options, than puts
Call options by funds: $12.7M | Put options by funds: $7.38M
48% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 42
41% more capital invested
Capital invested by funds: $1B → $1.41B (+$407M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 35
1% less funds holding
Funds holding: 169 → 167 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$21.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$20M |
| 3 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$18.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.7M |
| 5 |
O
OrbiMed
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$29M |
| 2 |
Millennium Management
New York
|
-$26.8M |
| 3 |
AG
Artal Group
Luxembourg
|
-$16.6M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$10.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$6.3M |
ARRY Hedge Fund Activity: Q4 2016 in Review
167 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2016, worth a combined $1.41B — up 41% from $1B a quarter earlier.
Fund positioning in ARRY was balanced in Q4 2016: 35 funds opened new positions, 35 closed out, 62 added to existing stakes and 42 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $21.3M. The largest seller was Sarissa Capital Management, exiting entirely with an estimated $29M sold.
- 167 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2016, down from 169 in Q3 2016.
- Funds reported $1.41B of Array Biopharma Inc stock for Q4 2016, up 41% quarter-over-quarter.
- 35 funds opened new Array Biopharma Inc positions in Q4 2016 and 35 closed out, a net change of 0 holders.
- The largest Array Biopharma Inc buyer in Q4 2016 was Morgan Stanley, an estimated $21.3M added.
- The largest Array Biopharma Inc seller in Q4 2016 was Sarissa Capital Management, an estimated $29M sold.
Based on aggregated 13F filings for Q4 2016.